Published 6 days ago • loading... • Updated 4 days ago

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with ...

Summary by Enid News & Eagle

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils

4 Articles

All

Left

Center

Right

Enid News & Eagle

Lean Left

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils

5 days ago

Read Full Article

hcplive.com

Dupilumab Effective for Atopic Dermatitis in Patients Aged 6 Months to 11 Years

These findings result from a systematic review and meta-analysis looking at the utilization of dupilumab among children and adolescents with atopic dermatitis.

4 days ago

Read Full Article

The Tech Daily Post

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy. The approval in Japan was based on data from the landmark BOREAS phase 3 study. The study evaluated Dupixent added to background maximal standard-of-care inhaled therapy (with…

5 days ago

Read Full Article